Voir la source de Buried Solutions To Enol

1 This study compared plume temperature and force of two ICS/LABA combination products: fluticasone propionate/formoterol 125/5?��g (flutiform?, FP/FORM) and fluticasone propionate/salmeterol 125/50?��g (Seretide?, FP/SAL), delivered via metered-dose inhalers. Methods:?Inhalers were held in a fixed device and operated according to manufacturers' instructions. A thermal imaging video camera, operating at 30 frames per second, recorded plume temperature from the side of the device. The same test rig, with a copper disc attached to a sensitive load cell measured plume force over a range of distances 25?mm to 95?mm from the device. Results:?At 25?mm the FP/FORM plume was +6��C, while that of the FP/SAL plume was ?38��C. [http://www.selleckchem.com/products/SNS-032.html SNS-032 nmr] The FP/SAL plume was colder over a longer distance. The force of the FP/SAL plume was greater than that of the FP/FORM device at all distances measured: mean force recorded for FP/SAL was 218.0?mN compared to 104.0?mN for FP/FORM. Conclusion:?The FP/SAL plume was considerably colder than the FP/FORM [http://www.selleckchem.com/screening/fda-approved-drug-library.html FDA approved Drug Library screening] plume particularly over shorter distances. The FP/SAL plume was more forceful, approximately twice that of the FP/FORM device. These differences may be due to different types of HFA propellant with different boiling points, the excipients in each formulation, and actuator geometry. The plume characteristics of the FP/FORM device may facilitate lung deposition and lessen impaction in the throat. 1?Gabrio BJ. Int J Pharm 1999;186:3�C12 Sponsor:?MUNDIPHARMA RESEARCH LTD REN Y, SU X, KANG J Department of Respiratory Disease, The First Hospital of China Medical University, Shenyang, China Background and Purpose:?Airway inflammation, airway remodeling and airway hyperresponsiveness are major aspects of asthma pathology. Histone deacetylase inhibitors have a broad effects that demonstrate therapeutic effects in animal models of chronic inflammatory diseases. [http://en.wikipedia.org/wiki/Enol Enol] In this study, we investigated the effects of Tubastatin A Hcl, a selective HDAC6 inhibitor, on the development of chronic allergic airway disease mice with airway inflammation, airway remodeling and airway hyperresponsiveness. Methods:?Wild-type BALB/C mice were sensitized intraperitoneally three times with ovalbumin (OVA) and aluminum hydroxide gel (on weeks 0, 1, 2) and nebulized 1 week (early phase) or 8 weeks (prolonged phase). Ovalbumin-exposed mice were treated with Tubastatin A Hcl or vehicle control. Airway inflammation was assessed by bronchoalveolar lavage fluid cell counts and HE staining of lung tissue sections. Airway remodeling was assessed by Alcian blue-Periodic acid Schiff staining and Masson trichrome staining. Airway hyperresponsiveness was assessed by plethysmography measurement of airway resistance. Results:?Tubastatin A Hcl treatment reliefed airway inflammation compared with vehicle treated mice (P?